TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26423264

Group type: EXPERIMENTAL
Intervention: New community-based reproductive health intervention model (self-designed handbooks, health lectures, free medical consultations)
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Traditional community intervention (limited reproductive information and education)
Number of subjects: 2100
Study: 25536958

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: non-LNG-IUS
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control
Number of subjects: 190
Study: 24159564

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 2708
Study: 21429809

Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone 12 mg once daily (QD)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone 12 mg every other day (alternate-day dosing)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study: 18329071

Group type: EXPERIMENTAL
Intervention: NSAID (lornoxicam)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 100
Study: 16995554

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 20

Group type: COMPARATOR
Intervention: epi-LASIK
Number of subjects: 20
Study: 12687868

Group type: EXPERIMENTAL
Intervention: Cardioverter defibrillator with enhancements On
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cardioverter defibrillator with enhancements Off
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cardioverter defibrillator shock therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Separate shock vector for atrial shock conversions
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ATP on atrial tachyarrhythmias
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Delivered shocks on AF
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Separate shock vector for induced AF
Number of subjects: 89
Study: 11155609

Group type: EXPERIMENTAL
Intervention: Breastfeeding education intervention (1 1/2-hour mandated session + optional self-paced tutorial)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control site (no intervention)
Number of subjects: 100
Study: 8823558

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg once daily for six weeks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Itraconazole 50 mg once daily for six weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 71
Study: 1315661

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferral of treatment
Number of subjects: 0
Study: 6835563

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31607424

Group type: EXPERIMENTAL
Intervention: Dopaminergic medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive impairment in PD patients
Number of subjects: 0
Study: 29924010

Group type: EXPERIMENTAL
Intervention: LED therapy (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bath therapy (n = 30)
Number of subjects: 60
Study: 27138968

Group type: EXPERIMENTAL
Intervention: Tofacitinib 30 mg twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Microgynon 30® tablet (30 μg EE and 150 μg LN)
Number of subjects: 19
Study: 24502751

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment using the Daytime Insomnia Symptom Scale (DISS) administered 4 times daily for 7 days.
Number of subjects: 55
Study: 19303591

Group type: EXPERIMENTAL
Intervention: Novel verbs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel nouns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-course of mapping novel words
Number of subjects: 0
Study: 15018324

Group type: EXPERIMENTAL
Intervention: Single intracisternal injection of recombinant tPA (400 microg/ml, 500 microg/ml, 700 microg/ml, 800 microg/ml in 20 ml distilled water at pH 7)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Single intracisternal injection of recombinant tPA
Number of subjects: 7
Study: 11136561

Group type: EXPERIMENTAL
Intervention: Class II radical hysterectomy
Number of subjects: 243

Group type: COMPARATOR
Intervention: Class III radical hysterectomy
Number of subjects: 243
Study: 10771973

Group type: EXPERIMENTAL
Intervention: Inhaled dexamethasone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7511229

Group type: EXPERIMENTAL
Intervention: Pacing System Analyzer 1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Pacing System Analyzer 2
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Pacing System Analyzer 3
Number of subjects: 99

Group type: COMPARATOR
Intervention: Manual Measurement
Number of subjects: 99
Study: 3044798

Group type: EXPERIMENTAL
Intervention: Six special blue fluorescent lamps with incubator sides draped with white cloth
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard phototherapy units equipped with fluorescent lights
Number of subjects: 101

Group type: COMPARATOR
Intervention: Halide lamp
Number of subjects: 101
Study: 11980553

Group type: EXPERIMENTAL
Intervention: Published RCTs
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 447

Group type: COMPARATOR
Intervention: Unpublished RCTs
Number of subjects: 447
Study: 31048096

Group type: EXPERIMENTAL
Intervention: Mouse-based contingent attention training (MCAT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control condition (free interpretation without feedback)
Number of subjects: 41
Study: 30017261

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) responders and remitters
Number of subjects: 91
Study: 26931279

Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 μg/d (subcutaneous injection)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Zoledronic Acid (ZOL) 5 mg/yr (intravenous infusion)
Number of subjects: 59
Study: 24852357

Group type: EXPERIMENTAL
Intervention: Previously received mental health treatment
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: 1 day depressive symptoms
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Medicaid
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Alcohol abuse and prior mental health care
Number of subjects: 266
Study: 23268574

Group type: EXPERIMENTAL
Intervention: Trap door (TD) technique
Number of subjects: 13

Group type: COMPARATOR
Intervention: Triangular distal wedge (TW) procedure
Number of subjects: 13
Study: 20391044

Group type: EXPERIMENTAL
Intervention: Cyanocobalamin nasal spray for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 36
Study: 18586810

Group type: EXPERIMENTAL
Intervention: Strength training and stretching
Number of subjects: 101

Group type: COMPARATOR
Intervention: Stretching only
Number of subjects: 101
Study: 15824145

Group type: EXPERIMENTAL
Intervention: RARbeta2 P2 promoter methylation in early stage breast cancers
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: RARbeta2 P2 promoter methylation in RPFNA samples
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: RARbeta2 P2 promoter methylation stratified by Masood cytology index
Number of subjects: 38
Study: 12094192

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with ST-segment resolution at 90 minutes
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with ST-segment resolution at 180 minutes
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: ST-segment resolution at 90 minutes
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: ST-segment resolution at 180 minutes
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: Patients aged >70 years, Killip class >1, and anterior infarctions
Number of subjects: 2352
Study: 10340829

Group type: EXPERIMENTAL
Intervention: Monovalent antivenom (ammonium sulphate fractionation)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Polyvalent antivenom (caprylic acid fractionation)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both antivenoms
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Monovalent antivenom
Number of subjects: 53
Study: 8948272

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Alendronate 20/5 mg
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 478
Study: 1682685

Group type: EXPERIMENTAL
Intervention: Capsaicin (NANC stimulant)
Number of subjects: 24
Study: 6751268

Group type: EXPERIMENTAL
Intervention: Radical surgery only (Wertheim‐Meigs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radical surgery followed by postoperative external radiotherapy
Number of subjects: 60
Study: 31335587

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 303

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 303
Study: 29921404

Group type: EXPERIMENTAL
Intervention: Combination of contraceptive pill + local treatment + pulsed‐vacuum light (Group I)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Contraceptives + pulsed‐vacuum light (Group II)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Local treatment only (Group III)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Combination of contraceptives + pulsed‐vacuum light (Group II)
Number of subjects: 116
Study: 27208343

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 25057173

Group type: EXPERIMENTAL
Intervention: Vandetanib (100 mg/day) plus docetaxel (75 mg/m(2) every 21 days)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Vandetanib plus docetaxel
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1391
Study: 22173910

Group type: EXPERIMENTAL
Intervention: Flavanol-rich chocolate (FRC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cocoa-liquor-free control chocolate (CC)
Number of subjects: 20
Study: 19171948

Group type: EXPERIMENTAL
Intervention: Sleep group (practiced in the evening, retention testing the following morning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-sleep group (practiced in the morning, retention testing in the evening)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants (not specified if they practiced in the evening or morning)
Number of subjects: 0
Study: 17205032

Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg intravenously twice a day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg intravenously four times daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rescue combination therapy (open-label)
Number of subjects: 90
Study: 15867118

Group type: EXPERIMENTAL
Intervention: Skill-based HIV/STD intervention
Number of subjects: 682

Group type: COMPARATOR
Intervention: Information-based HIV/STD intervention
Number of subjects: 682

Group type: COMPARATOR
Intervention: Health promotion control intervention
Number of subjects: 682
Study: 12509907

Group type: EXPERIMENTAL
Intervention: Tinnitus retraining therapy (TRT) with drugs
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group with tinnitus masking and drugs
Number of subjects: 225
Study: 9801090

Group type: EXPERIMENTAL
Intervention: External beam radiation for prostate cancer (PFH group)
Number of subjects: 920

Group type: COMPARATOR
Intervention: External beam radiation for prostate cancer (Sporadic group)
Number of subjects: 920
Study: 7644082

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 25 mg, 50 mg, or 100 mg
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 2503080

Group type: EXPERIMENTAL
Intervention: Support with human chorionic gonadotrophin (2500 IU) given three and six days after ovulation induction with 10,000 IU human chorionic gonadotrophin.
Number of subjects: 115

Group type: COMPARATOR
Intervention: No hormonal support (control group).
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Support with human chorionic gonadotrophin (2500 IU).
Number of subjects: 115
Study: 952109

Group type: EXPERIMENTAL
Intervention: Combined polychemotherapy with high doses of cytostatics applied intermittently after radical surgery.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Radical surgical operation without aftertreatment.
Number of subjects: 220
Study: 31271312

Group type: EXPERIMENTAL
Intervention: self‐monitoring of blood glucose and four sensor wears (group C)
Number of subjects: 148

Group type: COMPARATOR
Intervention: self‐monitoring of blood glucose (group A)
Number of subjects: 148
Study: 28866675

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (2 intravitreal loading doses at 4-week intervals)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dry AMD (control group)
Number of subjects: 50
Study: 25458726

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (1052 of 2327 women, 45%)
Number of subjects: 47494

Group type: COMPARATOR
Intervention: Standard care (215 of 2062 women, 10%)
Number of subjects: 47494

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (whole population)
Number of subjects: 47494

Group type: COMPARATOR
Intervention: Standard care (whole population)
Number of subjects: 47494
Study: 23744759

Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac (IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac (IM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac (IV) 18.75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac (IV) 37.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cataflam 50 mg (oral)
Number of subjects: 0
Study: 21816980

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 814

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 814
Study: 19736496

Group type: EXPERIMENTAL
Intervention: Management of HCV in hemodialysis patients at Prince Salman Center for kidney disease (PSCKD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevalence of HCV in hemodialysis patients in Saudi Arabia
Number of subjects: 0
Study: 17147046

Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin administered subcutaneously at a dose of 4,000 IU once a day for 10 days, combined with venovenous hemofiltration performed at the first and last day of the protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy (cortisone, vasoactive agents, and vitamin complexes) administered in physiological solution intravenously twice daily for 10 days
Number of subjects: 20
Study: 12626791

Group type: EXPERIMENTAL
Intervention: Direct access (no routine follow-up but access to rapid review on request)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Routine review (control)
Number of subjects: 209
Study: 10840422

Group type: EXPERIMENTAL
Intervention: Monthly BCG
Number of subjects: 236

Group type: COMPARATOR
Intervention: Alternating monthly interferon-alpha and BCG
Number of subjects: 236
Study: 9175061

Group type: EXPERIMENTAL
Intervention: Ultrasonographic guidance for catheter insertion (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blind technique for catheter insertion (Group B)
Number of subjects: 0
Study: 8269913

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Phenytoin and Carbamazepine
Number of subjects: 51
Study: 3107462

Group type: EXPERIMENTAL
Intervention: Norfloxacin (800 mg)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Thiamphenicol (2.5 g)
Number of subjects: 168
Study: 30730452

Group type: EXPERIMENTAL
Intervention: Nursing bedside report
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not participating in nursing bedside report)
Number of subjects: 0
Study: 28285862

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified, but implied as the pain without intervention)
Number of subjects: 40
Study: 27987591

Group type: EXPERIMENTAL
Intervention: Nintedanib plus pemetrexed
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo plus pemetrexed
Number of subjects: 713
Study: 24394586

Group type: EXPERIMENTAL
Intervention: Cantilevered fixed dental prostheses (CFDPs)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Natural second premolar (non-cantilever group)
Number of subjects: 62
Study: 22879908

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20002719

Group type: EXPERIMENTAL
Intervention: Paracetamol 15 mg/kg/dose every 4 h
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ibuprofen 10 mg/kg/dose every 8 h
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paracetamol and Ibuprofen (both groups)
Number of subjects: 100
Study: 17362317

Group type: EXPERIMENTAL
Intervention: Doxorubicin/cisplatin/paclitaxel (TAP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Doxorubicin/cisplatin (AP)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: TAP
Number of subjects: 134
Study: 12765607

Group type: EXPERIMENTAL
Intervention: Antibodies against beta-amyloid (aggregated Abeta(42))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10905644

Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.1 microg/kg/min
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Fenoldopam 0.3 microg/kg/min
Number of subjects: 107

Group type: COMPARATOR
Intervention: Fenoldopam 0.01 microg/kg/min
Number of subjects: 107

Group type: COMPARATOR
Intervention: Fenoldopam 0.03 microg/kg/min
Number of subjects: 107
Study: 9140791

Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 358

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 358
Study: 1419452

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 6145426

Group type: EXPERIMENTAL
Intervention: fluperlapine 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: fluperlapine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: clozapine 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: clozapine 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 3527402

Group type: EXPERIMENTAL
Intervention: Chlorambucil (CB) and Prednisone (P) for induction therapy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Chlorambucil (CB) and Prednisone (P) for consolidation
Number of subjects: 178

Group type: COMPARATOR
Intervention: Cytosine arabinoside and Cyclophosphamide for consolidation
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Responders (CR + PR)
Number of subjects: 178
Study: 29895236

Group type: EXPERIMENTAL
Intervention: Compression garment (18-21 mmHg) worn on one calf until follow-up
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-compressed calf)
Number of subjects: 0
Study: 29200573

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Sham (Control)
Number of subjects: 1
Study: 25795406

Group type: EXPERIMENTAL
Intervention: Trabectedin (1·2 mg/m² via central venous line over 24 h on day 1 of a 21 day treatment cycle)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 76
Study: 23940307

Group type: EXPERIMENTAL
Intervention: Spironolactone (titrated to 25 or 50 mg daily)
Number of subjects: 1663
Study: 20886786

Group type: EXPERIMENTAL
Intervention: Deep puncture at ST 25 with electric stimulation
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Shallow puncture at ST 25 with electric stimulation
Number of subjects: 95

Group type: COMPARATOR
Intervention: Medication group (Duphalac)
Number of subjects: 95
Study: 18186979

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 30
Study: 17147493

Group type: EXPERIMENTAL
Intervention: ELISPOT assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICS assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bulk culture CTL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MHC I tetramer staining
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN‐gamma ELISPOT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN‐gamma intracellular cytokine staining
Number of subjects: 0
Study: 14555263

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (2 mg every 3 months) and calcium (1000 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (2 mg every 3 months) and calcium (1000 mg daily) with 700 IU vitamin D daily in the second year
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment
Number of subjects: 14
Study: 11078987

Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration (UIC) measured in microg/l
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: UIC in children and male adolescents
Number of subjects: 412

Group type: COMPARATOR
Intervention: Comparison of UIC data with WHO criteria and previous non-randomized Swiss UIC data
Number of subjects: 412
Study: 9097349

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation in assist/control mode (nIPPV)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nasal pressure support ventilation (nPSV)
Number of subjects: 14
Study: 1316330

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily for 14 days
Number of subjects: 16